MedTrace Logo

Pharmacokinetics and Safety of Ertapenem in the Postpartum Period

NCT01587495 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2015-05-20

No results posted yet for this study

Summary

The investigators are doing this study to learn more about the dosing and safety of ertapenem in women with suspected serious infections less than 42 days from the delivery of their infant.

Conditions

  • Endometritis

Interventions

DRUG

Ertapenem

Ertapenem will be administered by intravenous infusion per the FDA approved standard of care (1 gram q24 hours). as follows:

Sponsors & Collaborators

  • Daniel Benjamin

    lead OTHER

Principal Investigators

  • Geeta Swamy, MD · Duke University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01587495 on ClinicalTrials.gov